PE20220581A1 - Composicion farmaceutica para suministro nasal - Google Patents

Composicion farmaceutica para suministro nasal

Info

Publication number
PE20220581A1
PE20220581A1 PE2022000019A PE2022000019A PE20220581A1 PE 20220581 A1 PE20220581 A1 PE 20220581A1 PE 2022000019 A PE2022000019 A PE 2022000019A PE 2022000019 A PE2022000019 A PE 2022000019A PE 20220581 A1 PE20220581 A1 PE 20220581A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition
nasal
nasal supply
opioid
Prior art date
Application number
PE2022000019A
Other languages
English (en)
Inventor
Jonas Savmarker
Robert Ronn
Andreas Fischer
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of PE20220581A1 publication Critical patent/PE20220581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona una formulacion de composicion farmaceutica solida para administracion nasal que comprende una cantidad farmacologicamente eficaz de un antagonista de opioide seleccionado de naloxona, nalmefeno o naltrexona y un vehiculo farmaceuticamente aceptable que incluyen disacaridos por ejemplo, lactosa o trehalosa; y dextrinas por ejemplo, ciclodextrinas o maltodextrinas. Ademas, pueden comprender un sacarido de alquilo, preferentemente un ester de sacarosa, tal como monolaurato de sacarosa. Dicha composicion se encuentra en forma de polvo producido por secado por pulverizacion, que posteriormente se carga en aplicadores nasales. Dicha composicion puede emplearse en el tratamiento de sobredosis de opioides en sujetos.
PE2022000019A 2019-07-09 2020-05-18 Composicion farmaceutica para suministro nasal PE20220581A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/506,023 US10653690B1 (en) 2019-07-09 2019-07-09 Pharmaceutical composition for nasal delivery
PCT/GB2020/051207 WO2021005325A1 (en) 2019-07-09 2020-05-18 Pharmaceutical composition for nasal delivery

Publications (1)

Publication Number Publication Date
PE20220581A1 true PE20220581A1 (es) 2022-04-20

Family

ID=70736393

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000019A PE20220581A1 (es) 2019-07-09 2020-05-18 Composicion farmaceutica para suministro nasal

Country Status (14)

Country Link
US (1) US10653690B1 (es)
EP (1) EP3996687A1 (es)
JP (1) JP2022540227A (es)
KR (1) KR20220034153A (es)
CN (1) CN114096249A (es)
AU (1) AU2020311020A1 (es)
BR (1) BR112022000260A2 (es)
CA (1) CA3145965A1 (es)
CL (1) CL2022000033A1 (es)
CO (1) CO2022000254A2 (es)
IL (1) IL289513A (es)
MX (1) MX2022000368A (es)
PE (1) PE20220581A1 (es)
WO (1) WO2021005325A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
WO2021102328A1 (en) * 2019-11-21 2021-05-27 Torralva Medical Therapeutics Llc Prophylaxis and reversal of stimulant and opioid/opiate overdose and/or toxic exposure
JP2023526098A (ja) 2020-05-18 2023-06-20 オレクソ・アクチエボラゲット 薬物送達のための新しい医薬組成物
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
US11617716B2 (en) * 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
KR20240111761A (ko) 2021-11-25 2024-07-17 오렉쏘 에이비 생체의약품 화합물을 포함하는 약학적 조성물
GB202117005D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
GB202117015D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
GB202117007D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
US12005185B2 (en) 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
ATE196427T1 (de) 1993-12-06 2000-10-15 Takeda Chemical Industries Ltd Zusammensetzung mit verbesserter wasserlöslichkeit, enthaltend eine wasserunlösliche oder an wasser schwerunlösliche verbindung
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
WO1999046055A1 (fr) 1998-03-10 1999-09-16 Valois S.A. Reservoir, procede de remplissage du reservoir et dispositif de distribution du produit fluide contenu dans le reservoir
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
AU2003296954A1 (en) 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
ES2414084T3 (es) * 2003-02-24 2013-07-18 Pharmaceutical Productions Inc. Sistema de administración de fármacos por vía transmucosa
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
TWI288649B (en) 2003-10-09 2007-10-21 Bioactis Ltd Powdery medicine dispensing device for nasal cavity
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1305474C (zh) * 2004-10-13 2007-03-21 北京国药龙立生物医药新技术有限公司 盐酸纳美芬鼻腔给药制剂
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
AU2006212021B2 (en) 2005-02-10 2010-09-30 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
CN101594848B (zh) 2006-09-15 2014-10-29 艾可制药有限公司 包含药物活性物质和乳化剂的颗粒及其制备方法
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
JP5437232B2 (ja) 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
AU2010299607B2 (en) 2009-09-25 2016-07-28 Tonix Medicines, Inc. Formulations comprising triptan compounds
CN102068697B (zh) * 2010-12-30 2013-10-16 宜昌人福药业有限责任公司 含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
SG194927A1 (en) 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
EP3082817A4 (en) 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3174534A1 (en) 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
SI3220893T1 (sl) 2014-11-14 2023-09-29 Asoltech Srl Sestavek na osnovi COQ10
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) * 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
CA2975562C (en) 2015-02-17 2020-04-28 Eli Lilly And Company Nasal powder formulation for treatment of hypoglycemia
US20180296679A1 (en) 2015-04-08 2018-10-18 Chang-Chun Ling Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
AU2017206041B2 (en) * 2016-01-08 2022-07-28 Ohio State Innovation Foundation Treatments and prevention of opioid neonatal abstinence syndrome
KR102263900B1 (ko) 2016-03-16 2021-06-14 골든 오메가 노르웨이 에이에스 오메가-3 지방산 유도체를 포함하는 분말 및 정제 및 이의 제조 방법
US11319376B2 (en) * 2016-08-03 2022-05-03 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
AU2017336776A1 (en) 2016-09-28 2019-03-21 Chrono Therapeutics Inc. Transdermal drug delivery device for delivering opioids
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
EP3538189A4 (en) 2016-11-09 2020-04-22 Opiant Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES
IL266674B2 (en) 2016-11-18 2024-09-01 Opiant Pharmaceuticals Inc Preparations, devices and methods for the use of nalamfen and dodecyl maltozide through the nose for the treatment of an opioid overdose.
CN106361700A (zh) * 2016-11-25 2017-02-01 威海恒基伟业信息科技发展有限公司 盐酸纳美芬鼻腔给药制剂
US10394770B2 (en) 2016-12-30 2019-08-27 General Electric Company Methods and systems for implementing a data reconciliation framework
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
JP7334145B2 (ja) 2017-08-20 2023-08-28 ネイサス ファーマ リミテッド 鼻腔内送達用乾燥粉末組成物
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
CN109953952A (zh) * 2017-12-25 2019-07-02 王旭宁 盐酸纳美芬鼻腔给药制剂

Also Published As

Publication number Publication date
JP2022540227A (ja) 2022-09-14
WO2021005325A1 (en) 2021-01-14
IL289513A (en) 2022-03-01
CO2022000254A2 (es) 2022-04-29
MX2022000368A (es) 2022-02-03
KR20220034153A (ko) 2022-03-17
CA3145965A1 (en) 2021-01-14
AU2020311020A1 (en) 2022-03-03
BR112022000260A2 (pt) 2022-03-03
CL2022000033A1 (es) 2022-08-19
EP3996687A1 (en) 2022-05-18
CN114096249A (zh) 2022-02-25
US10653690B1 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
PE20220581A1 (es) Composicion farmaceutica para suministro nasal
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
RS53995B1 (en) NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF OPIOID SUBSTANCE
GB2545368A (en) Diversion-resistant opioid formulations
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
AR089130A1 (es) FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO
MX2015012302A (es) Composiciones tópicas y métodos de tratamiento para trastornos de la piel.
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
AR095160A1 (es) Formulaciones farmacéuticas a prueba de alteraciones
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
BR112012029064A2 (pt) formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan
AR079654A1 (es) Combinaciones anticancerosas de farmacos a base de artemisinina y otros agentes quimioterapeuticos. uso. composicion farmaceutica. procedimiento de preparacion. metodo de tratamiento.
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
MX2019008870A (es) Agente terapeutico para enfermedades hepaticas.
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
MX2018010194A (es) Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas.
BR112016005361B8 (pt) Composto, composição, e, uso de um composto
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου